Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Pegaptanib Sodium	All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.

Participant Flow:   Overall Study

	Pegaptanib Sodium
STARTED	81[1]
COMPLETED	49
NOT COMPLETED	32
Adverse Event	5
Lack of Efficacy	17
Withdrawal by Subject	5
unknown	5

Reporting Groups

	Description
Pegaptanib Sodium	All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.

Baseline Measures

	Pegaptanib Sodium
Number of Participants   [units: participants]	81
Age   [units: years] Mean ± Standard Deviation	76.3 ± 6.7
Gender   [units: participants]
Female	47
Male	34

1.  Primary:

Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS)   [ Baseline, 54 Weeks ]

2.  Secondary:

Change From Baseline in Visual Acuity   [ Baseline, 6 weeks, 12 weeks, 54 weeks ]

3.  Secondary:

Number of Subjects Gaining Vision   [ 54 weeks or at early termination ]

4.  Secondary:

Number of Subjects Maintaining Vision   [ 54 weeks or at early termination ]

5.  Secondary:

Number of Subjects With Severe Visual Loss   [ 54 weeks or at early termination ]

6.  Secondary:

Number of Subjects With a Distance Visual Acuity of > 20/200 at Baseline and Progressing to (<= 20/200)   [ 54 weeks ]

7.  Secondary:

Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25).   [ Baseline, 54 weeks or at early termination ]